The bar chart illustrates the distribution of a drug company’s total sales across three regions—America, Europe, and Asia—between 2002 and 2006. Overall, the data reveals a clear shift in market dominance from America to Asia, while Europe’s contribution remained relatively volatile throughout the period.
In 2002, America was the company’s primary market, accounting for 41% of total sales, followed by Europe at 34% and Asia at 25%. However, America’s market share declined steadily to 27% by 2004, before recovering slightly to reach 30% in 2006. Conversely, Asia demonstrated a robust and consistent growth trajectory, increasing its share annually from 25% in 2002 to 40% in 2006, ultimately becoming the company's largest market.
Europe’s sales performance was more erratic. After starting at 34% in 2002, its share rose to 35% in 2003 and peaked at 38% in 2004. Following this peak, the region’s contribution to total sales fell to 34% in 2005 and further declined to 30% by the end of the period. By 2006, both America and Europe contributed an identical 30% to the company's total sales, significantly trailing behind Asia’s 40%.